Table 2.
Overall sensitivity and specificity of the app in detecting skin premalignancy and malignancy, including subgroup analyses between the iOS and Android devices, melanocytic versus nonmelanocytic skin lesions, skin fold lesion areas versus smooth skin lesion areas, suspicious skin lesions versus benign control lesions, skin lesions identified after GP and nondermatology referrals versus follow-up consultations of known patients at the outpatient clinics
| Assessment type | N (%) | Sensitivity (95% CI), % | p value | Specificity (95% CI), % | p value |
|---|---|---|---|---|---|
| Overall app accuracy | 785 (100) | 86.9 (82.3–90.7) | 70.4 (66.2–74.3) | ||
|
| |||||
| Android device iOS device | 425 (54.1) 360 (45.9) | 83.0 (75.7–88.8)* 91.0 (84.9–95.3)* | 0.02 | 71.5 (65.9–76.7) 69.0 (62.6–75.0) |
0.27 |
|
| |||||
| Melanocytic skin lesions Nonmelanocytic skin lesions | 179 (22.8) 606 (77.2) |
81.8 (59.7–94.8) 87.4 (82.6–91.2) |
0.26 | 73.3 (65.6–80.0) 69.1 (64.0–73.9) |
0.17 |
|
| |||||
| Skin fold lesion areas Smooth skin lesion areas | 138 (17.6) 647 (82.4) |
92.9 (85.3–97.4)* 84.2 (78.2–89.1)* |
0.01 | 56.6 (42.3–70.2)* 72.0 (67.6–76.1)* |
0.02 |
|
| |||||
| Suspicious skin lesions Benign control lesions | 418 (53.3) 367 (46.7) |
86.9 (82.3–90.7) | 45.5 (37.1–54.0)*** 80.1 (75.7–84.1)*** |
<0.001 | |
|
| |||||
| GP and nondermatology referrals Follow-up consultations | 213 (27.1) 205 (26.1) |
89.6 (83.4–94.1) 84.0 (76.6–89.8) |
0.09 | 39.1 (27.6–51.6) 51.4 (39.4–63.2) |
0.07 |
*
p < 0.05
***
p < 0.001.